Q2 2024 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2024-08-14 · accession 0001214659-24-014472
$959.5M
Reported value
32
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY, INC. | $115.9M | 12.1% | 3,670,206 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS, INC | $93.5M | 9.75% | 2,650,150 | Common | SOLE |
| 00370M103 | ABVX | Abivax SA | $80.1M | 8.34% | 6,056,596 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $62.6M | 6.53% | 3,295,350 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $58.7M | 6.12% | 6,964,375 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC. | $49.8M | 5.19% | 12,362,205 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $41.8M | 4.36% | 149,283 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS, INC. | $40.9M | 4.27% | 2,272,728 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS, INC. | $40.2M | 4.19% | 879,344 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS, INC. | $37.3M | 3.88% | 3,185,185 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX, INC. | $36.4M | 3.79% | 5,319,148 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $31.8M | 3.31% | 1,989,103 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $29.3M | 3.06% | 1,423,642 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $27.3M | 2.84% | 694,547 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $26.1M | 2.72% | 2,890,816 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS, INC. | $25.1M | 2.62% | 2,761,861 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $23.3M | 2.43% | 3,858,000 | Common | SOLE |
| 834203200 | — | SOLENO THERAPEUTIVS, INC. | $22.4M | 2.34% | 550,000 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $21.9M | 2.29% | 486,957 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $19.0M | 1.98% | 1,477,593 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS, INC. | $15.1M | 1.58% | 556,317 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES, INC. | $13.8M | 1.44% | 2,008,340 | Common | SOLE |
| 92840H202 | — | VISTAGEN THERAPEUTICS INC | $9.3M | 0.97% | 2,676,580 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $8.3M | 0.87% | 584,955 | Common | SOLE |
| 30233G209 | EYPT | EyePoint Pharmaceuticals, Inc. | $8.0M | 0.84% | 922,335 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS, INC. | $5.9M | 0.61% | 1,276,574 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $5.0M | 0.52% | 4,000,000 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $3.7M | 0.39% | 2,240,809 | Common | SOLE |
| 037326105 | ANTX | AN2 Therapeutics, Inc. | $3.3M | 0.35% | 1,555,118 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $2.1M | 0.22% | 899,999 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES, INC | $730,410 | 0.08% | 316,195 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO, INC | $649,227 | 0.07% | 86,795 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.